Capital is available, but only for companies with clean data, clear differentiation, and a believable commercial path.
Four days at Jefferies London tends to compress a year of market thinking into a few conversations.
In 2025, the message was consistent across rooms: capital is available, but only for companies with clean data, clear differentiation, and a believable commercial path.
Reporting for Onyx, I attended Jefferies 2025 to get the full scoop.
I hope you enjoy watching!
Yours sincerely,
Dr. Adil Ali
A fully funded pharma study plus multiple R&D collaborations signals rising strategic pull.
Cema-cel is already in the pivotal Phase 2 ALPHA3 frontline lymphoma trial, with manufacturing capacity sized for tens of thousands of annual doses (up to ~60,000 across products).
Nuvation is gaining real momentum after its first FDA approval, with IBTROZI now treating a growing number of patients with ROS1-positive lung cancer.
The British biotech recently secured a £5.5 million pre-Series A round to advance their lead asset, Myo-004, toward clinical candidate selection.
